BACKGROUND AND PURPOSE: Resolution of inflammation is mediated by endogenous molecules with anti-inflammatory and pro-resolving activities and they have generated new possibilities for the treatment of inflammatory diseases. Here, we have investigated the possible anti-hyperalgesic effects of two lipids, aspirin-triggered resolvin D1 (AT-RvD1) and its precursor, 17(R)-hydroxy-4Z,7Z,10Z,13Z,15E,17R,19Z-docosahexaenoic acid (17(R)HDoHE). EXPERIMENTAL APPROACH: The anti-hyperalgesic effects of both lipid mediators were evaluated, using mechanical and thermal stimuli, at different time-points in adjuvant-induced arthritis in rats. Cytokine levels were measured, and immunohistochemistry and real-time PCR for pro-inflammatory mediators were also performed. KEY RESULTS: The precursor of resolvin D series, 17(R)HDoHE, given systemically, inhibited the development and the maintenance of mechanical hyperalgesia in acute inflammation. Such effects were likely to be associated with modulation of both NF-κB and COX-2 in dorsal root ganglia and spinal cord. 17(R)HDoHE was also effective against sub-chronic pain. Unexpectedly, repeated treatment with 17(R)HDoHE did not modify paw and joint oedema in the sub-chronic model, while joint stiffness was prevented. Notably, AT-RvD1 exhibited marked anti-hyperalgesic effects in acute inflammation when given systemically. The efficacy of long-term treatment with either 17(R)HDoHE or AT-RvD1 was partly related to decreased production of TNF-α and IL-1β in rat hind paw. CONCLUSIONS AND IMPLICATIONS: Our findings provide fresh evidence for the anti-hyperalgesic properties of 17(R)HDoHE and its pro-resolution metabolite AT-RvD1. Such lipid mediators might be useful for treating pain associated with acute or chronic inflammation. LINKED ARTICLE This article is commented on by Xu and Ji, pp. 274-277 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476-5381.2011.01348.x.
BACKGROUND AND PURPOSE: Resolution of inflammation is mediated by endogenous molecules with anti-inflammatory and pro-resolving activities and they have generated new possibilities for the treatment of inflammatory diseases. Here, we have investigated the possible anti-hyperalgesic effects of two lipids, aspirin-triggered resolvin D1 (AT-RvD1) and its precursor, 17(R)-hydroxy-4Z,7Z,10Z,13Z,15E,17R,19Z-docosahexaenoic acid (17(R)HDoHE). EXPERIMENTAL APPROACH: The anti-hyperalgesic effects of both lipid mediators were evaluated, using mechanical and thermal stimuli, at different time-points in adjuvant-induced arthritis in rats. Cytokine levels were measured, and immunohistochemistry and real-time PCR for pro-inflammatory mediators were also performed. KEY RESULTS: The precursor of resolvin D series, 17(R)HDoHE, given systemically, inhibited the development and the maintenance of mechanical hyperalgesia in acute inflammation. Such effects were likely to be associated with modulation of both NF-κB and COX-2 in dorsal root ganglia and spinal cord. 17(R)HDoHE was also effective against sub-chronic pain. Unexpectedly, repeated treatment with 17(R)HDoHE did not modify paw and joint oedema in the sub-chronic model, while joint stiffness was prevented. Notably, AT-RvD1 exhibited marked anti-hyperalgesic effects in acute inflammation when given systemically. The efficacy of long-term treatment with either 17(R)HDoHE or AT-RvD1 was partly related to decreased production of TNF-α and IL-1β in rat hind paw. CONCLUSIONS AND IMPLICATIONS: Our findings provide fresh evidence for the anti-hyperalgesic properties of 17(R)HDoHE and its pro-resolution metabolite AT-RvD1. Such lipid mediators might be useful for treating pain associated with acute or chronic inflammation. LINKED ARTICLE This article is commented on by Xu and Ji, pp. 274-277 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476-5381.2011.01348.x.
Authors: Eric L Campbell; Nancy A Louis; Sarah E Tomassetti; Geraldine O Canny; Makoto Arita; Charles N Serhan; Sean P Colgan Journal: FASEB J Date: 2007-05-11 Impact factor: 5.191
Authors: Alexander M Binshtok; Haibin Wang; Katharina Zimmermann; Fumimasa Amaya; Daniel Vardeh; Lin Shi; Gary J Brenner; Ru-Rong Ji; Bruce P Bean; Clifford J Woolf; Tarek A Samad Journal: J Neurosci Date: 2008-12-24 Impact factor: 6.167
Authors: Luz A Cortes-Burgos; Ben S Zweifel; Steven L Settle; Robert A Pufahl; Gary D Anderson; Medora M Hardy; Dana E Weir; George Hu; Fernando A Happa; Zachary Stewart; Shanmugam Muthian; Matthew J Graneto; Jaime L Masferrer Journal: Eur J Pharmacol Date: 2009-07-04 Impact factor: 4.432
Authors: Jesmond Dalli; Jeremy W Winkler; Romain A Colas; Hildur Arnardottir; Chien-Yee C Cheng; Nan Chiang; Nicos A Petasis; Charles N Serhan Journal: Chem Biol Date: 2013-02-21
Authors: Sriram Krishnamoorthy; Antonio Recchiuti; Nan Chiang; Gabrielle Fredman; Charles N Serhan Journal: Am J Pathol Date: 2012-03-23 Impact factor: 4.307
Authors: Brian T Kalish; Hau D Le; Jonathan M Fitzgerald; Samantha Wang; Kyle Seamon; Kathleen M Gura; Karsten Gronert; Mark Puder Journal: Am J Physiol Gastrointest Liver Physiol Date: 2013-10-03 Impact factor: 4.052
Authors: Martin Giera; Andreea Ioan-Facsinay; Rene Toes; Fei Gao; Jesmond Dalli; André M Deelder; Charles N Serhan; Oleg A Mayboroda Journal: Biochim Biophys Acta Date: 2012-07-24